

Our versatile platforms have been used for the successful development of a broad range of vaccines. Below are some highlights:

Platform	Indication	Partner(s)	Stage
Bacterial: OMV	COVID-19	Ministry of Health, Welfare and Sport of The Netherlands	Phase I
Bacterial: OMV	Whooping Cough	Zhifei Lvzhu Biopharmaceutical Co., Ltd	Pre-clinical
Bacterial: OMV	Betacoronavirus	Coalition for Epidemic Preparedness Innovations	Pre-clinical
Bacterial: OMV	Meningitis B	Liaoning Chengda Biotechnology Co., Ltd	Pre-clinical
Bacterial: OMV	Gonorrhoea	National Institute of Allergy and Infectious Diseases Therapix Inc. CarbX	Pre-clinical Pre-Clinical
Viral: Inactivated	Polio	LG Chem Ltd. SINOVAC Biotech Ltd. Beijing Minhai Biological Technology Co., Ltd.	Marketed Marketed Marketed
Viral: Inactivated	Type 1 Diabetes (Coxsackievirus B)	Provention Bio, Inc.	Phase I
Viral: Inactivated	Acute Flaccid Myelitis (EV-D68)	National Institute of Allergy and Infectious Diseases	Phase I
Conjugation	Haemophilus influenzae Type B	Serum Institute of India PVT. LTD. Biological E Ltd Changchun BCHO Biotechnology Co.	Marketed Marketed Pre-clinical
Conjugation	Shigellosis	Institut Pasteur	Phase I / Phase II
Conjugation	Amyotrophic Lateral Sclerosis	German Center for Neurodegenerative Diseases	Pre-clinical
E.coli expression	Solid tumors	CimCure	Phase I



Website



LinkedIn



**Certificate
ISO 14001:2015**



**Certificate
ISO 14001 CO₂
Reductions
Management**



GMP Certificate

Learn more

Are you interested in our CDMO services or vaccine development platforms?

Our Business Development team is happy to discuss all possibilities with you.

Get in touch!

email us at: bd@intravacc.nl


Disclaimer: Intravacc assumes no liability or responsibility for any errors or omissions in the information included in this brochure, including forward looking statements. The information is provided "as is" with no guarantees of completeness, accuracy, or timeliness, and without warranties of any kind, expressed or implied.



Intravacc B.V., Utrecht Science Park Bilthoven, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
Phone: +31 30 792 03 00 - Mail: bd@intravacc.nl - www.intravacc.nl

Next-generation vaccines from the experts.

A global partner in the discovery, design, and development of your viral, bacterial, and conjugate vaccines.



Intravacc at a glance



100+

Years of experience



300+

Scientific publications in
peer-reviewed journals



50+

Customers worldwide




2,000 m²+

State-of-the-art facilities

Innovating your vaccines.

Intravacc is a customer-focused, global CDMO for therapeutic and infectious disease vaccines. With over 100 years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its knowledge and technology to biotech and pharmaceutical companies, governmental

agencies, and NGOs around the world. That expertise, combined with our proprietary Bacterial, Viral, Conjugate and Protein Expression vaccine platforms, as well as state-of-the-art and GMP facilities, positions us at the forefront of advancements in both human and veterinary vaccine and immunotherapy spaces.



Our CDMO Services at a glance.

Discovery and production


- **Vaccine strain design, modification, and optimization**
 - Bacterial strain construction
 - Viral strain construction
 - Viral rescue
- **Process development**
 - Cell banking
 - Seed lot production
 - Scale-up
 - Formulation
- **Pre-clinical characterization**
- **GMP manufacturing, 1-200 liters**

Characterization


- **Physicochemical**
 - Content
 - Higher-order structure
 - Antigenicity
 - Impurities
 - Excipient
 - Stability
- **Immunological**
 - Innate assays
 - Humoral assays
 - Cellular assays

Stellar track record

- 2 OMV vaccines successfully developed and transferred
- 1 conjugate AMR vaccine brought to market
- 1 cell-based viral vaccine brought to market
- 300+ scientific publications
- 50+ customers worldwide
- 10+ partnerships




Our proprietary vaccine development platforms.




Bacterial Vaccines

- Outer Membrane Vesicles
- Whole cell
- Sub-unit




Viral Vaccines

- Vero and HEK293 cells
- Attenuated & Inactivated
- Virus Like Particles



Conjugate Vaccines

- TTd, CRM197 & OMV carriers
- Oligo- and Polysaccharides
- Synthetic peptides



E.coli Expressed Vaccines

Protein expression platform for e.g. oncology and infectious diseases.